% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Striese:276772,
author = {F. Striese and C. Neuber and S. Gräßel and C. Arndt and
M. Ullrich and J. Steinbach and J. Pietzsch and R. Bergmann
and H.-J. Pietzsch and W. Sihver and M. Frenz and A.
Feldmann and M. P. Bachmann$^*$},
title = {{P}reclinical {C}haracterization of the 177{L}u-{L}abeled
{P}rostate {S}tem {C}ell {A}ntigen ({PSCA})-{S}pecific
{M}onoclonal {A}ntibody 7{F}5.},
journal = {International journal of molecular sciences},
volume = {24},
number = {11},
issn = {1422-0067},
address = {Basel},
publisher = {Molecular Diversity Preservation International},
reportid = {DKFZ-2023-01153},
pages = {9420},
year = {2023},
abstract = {Prostate specific membrane antigen (PSMA) is an excellent
target for imaging and treatment of prostate carcinoma
(PCa). Unfortunately, not all PCa cells express PSMA.
Therefore, alternative theranostic targets are required. The
membrane protein prostate stem cell antigen (PSCA) is highly
overexpressed in most primary prostate carcinoma (PCa) cells
and in metastatic and hormone refractory tumor cells.
Moreover, PSCA expression positively correlates with tumor
progression. Therefore, it represents a potential
alternative theranostic target suitable for imaging and/or
radioimmunotherapy. In order to support this working
hypothesis, we conjugated our previously described anti-PSCA
monoclonal antibody (mAb) 7F5 with the bifunctional chelator
CHX-A″-DTPA and subsequently radiolabeled it with the
theranostic radionuclide 177Lu. The resulting radiolabeled
mAb ([177Lu]Lu-CHX-A″-DTPA-7F5) was characterized both in
vitro and in vivo. It showed a high radiochemical purity
$(>95\%)$ and stability. The labelling did not affect its
binding capability. Biodistribution studies showed a high
specific tumor uptake compared to most non-targeted tissues
in mice bearing PSCA-positive tumors. Accordingly, SPECT/CT
images revealed a high tumor-to-background ratios from 16 h
to 7 days after administration of
[177Lu]Lu-CHX-A″-DTPA-7F5. Consequently,
[177Lu]Lu-CHX-A″-DTPA-7F5 represents a promising candidate
for imaging and in the future also for radioimmunotherapy.},
keywords = {Animals / Mice / Male / Pentetic Acid: chemistry / Tissue
Distribution / Prostate / Cell Line, Tumor / Antibodies,
Monoclonal: therapeutic use / Antibodies, Monoclonal:
chemistry / Stem Cells / Carcinoma: drug therapy / Lutetium:
chemistry / 177Lu-labeled antibody (Other) / CHX-A″-DTPA
(Other) / prostate cancer (Other) / prostate stem cell
antigen (Other) / Pentetic Acid (NLM Chemicals) /
Antibodies, Monoclonal (NLM Chemicals) / Lutetium (NLM
Chemicals)},
cin = {DD01},
ddc = {540},
cid = {I:(DE-He78)DD01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:37298374},
pmc = {pmc:PMC10253363},
doi = {10.3390/ijms24119420},
url = {https://inrepo02.dkfz.de/record/276772},
}